Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ubiquitin thioesterase OTUB1 is a human deubiquitinating enzyme (DUB) belonging to the OTU (ovarian tumor) superfamily of cysteine proteases[1][3][7]. It preferentially cleaves Lys48-linked polyubiquitin chains, regulating ubiquitin-dependent protein degradation and other signaling pathways such as the DNA damage response. OTUB1 functions by direct substrate deubiquitination and by a unique non-catalytic mechanism where it inhibits the E2 ubiquitin-conjugating enzyme UBC13, thereby suppressing Lys63-linked polyubiquitination involved in DNA repair[2]. OTUB1 participates in various multi-protein complexes, influencing processes such as RNA processing and cell adhesion[3]. Dysregulation of OTUB1 has been linked to cancer and abnormal immune responses. While no approved drugs currently target OTUB1, engineered ubiquitin variants selectively modulate its enzymatic activity in experimental settings[5].
Inhibition of deubiquitinase activity; Modulation of Lys48-linked polyubiquitin chain cleavage; Non-canonical inhibition of E2 ubiquitin-conjugating enzymes (specifically UBC13)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ubiquitin thioesterase OTUB1 (OTUB1).